{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T16:15:37Z","timestamp":1773332137448,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.lungcan.2017.12.018","type":"journal-article","created":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T13:23:51Z","timestamp":1515072231000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer"],"prefix":"10.1016","volume":"117","author":[{"given":"Ryo","family":"Ariyasu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Uchibori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Oh-hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Yoshizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Dotsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Saiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Kitazono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Yanagitani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Horiike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiko","family":"Inase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryohei","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2017.12.018_bib0005","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.lungcan.2017.12.018_bib0010","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2017.12.018_bib0015","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for nonsmall-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2017.12.018_bib0020","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2017.12.018_bib0025","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2017.12.018_bib0030","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2017.12.018_bib0035","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lungcan.2017.12.018_bib0040","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1158\/1078-0432.CCR-10-2277","article-title":"Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay","volume":"17","author":"Arcila","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2017.12.018_bib0045","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1158\/1078-0432.CCR-10-2692","article-title":"Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation","volume":"17","author":"Oxnard","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2017.12.018_bib0050","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291 an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2017.12.018_bib0055","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2017.12.018_bib0060","doi-asserted-by":"crossref","first-page":"11815","DOI":"10.1038\/ncomms11815","article-title":"Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients","volume":"10","author":"Chabon","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lungcan.2017.12.018_bib0065","doi-asserted-by":"crossref","first-page":"e000060","DOI":"10.1136\/esmoopen-2016-000060","article-title":"Mechanisms of resistance to EGFR-targeted drugs: lung cancer","volume":"1","author":"Morgillo","year":"2016","journal-title":"ESMO Open."},{"key":"10.1016\/j.lungcan.2017.12.018_bib0070","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1158\/2159-8290.CD-15-0399","article-title":"Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor","volume":"5","author":"Piotrowska","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2017.12.018_bib0075","doi-asserted-by":"crossref","first-page":"11815","DOI":"10.1038\/ncomms11815","article-title":"Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients","volume":"7","author":"Chabon","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lungcan.2017.12.018_bib0080","doi-asserted-by":"crossref","first-page":"8081","DOI":"10.1200\/JCO.2005.02.7078","article-title":"Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL\/INTACT gefitinib trials","volume":"23","author":"Bell","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2017.12.018_bib0085","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.lungcan.2017.12.018_bib0090","doi-asserted-by":"crossref","first-page":"51311","DOI":"10.18632\/oncotarget.9697","article-title":"The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer","volume":"7","author":"Gou","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2017.12.018_bib0095","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1093\/annonc\/mdv319","article-title":"EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients","volume":"26","author":"Planchard","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2017.12.018_bib0100","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.2147\/OTT.S106399","article-title":"Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations","volume":"9","author":"Wang","year":"2016","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.lungcan.2017.12.018_bib0105","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1200\/JCO.2013.49.5697","article-title":"EGFR-driven behavior and intrapatient T790M mutation heterogeneity of non-small-cell carcinoma with squamous histology","volume":"33","author":"Graziano","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2017.12.018_bib0110","doi-asserted-by":"crossref","first-page":"71782","DOI":"10.18632\/oncotarget.12373","article-title":"Early responses of EGFR circulating tumor DNA to EGFR tyrosine kinase inhibitors in lung cancer treatment","volume":"7","author":"Imamura","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2017.12.018_bib0115","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/jamaoncol.2014.257","article-title":"Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial","volume":"1","author":"Karachaliou","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2017.12.018_bib0120","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1200\/JCO.2016.66.7162","article-title":"Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer","volume":"34","author":"Oxnard","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2017.12.018_bib0125","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.lungcan.2017.07.015","article-title":"Detection of epidermal growth factor receptor gene T790M mutation in cytology samples using the cobas\u00ae EGFR mutation test","volume":"111","author":"Satouchi","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2017.12.018_bib0130","doi-asserted-by":"crossref","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.lungcan.2017.12.018_bib0135","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1158\/1078-0432.CCR-10-2571","article-title":"New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer","volume":"17","author":"Oxnard","year":"2011","journal-title":"Clin. Cancer Res."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950021730630X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950021730630X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T18:25:40Z","timestamp":1535135140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016950021730630X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":27,"alternative-id":["S016950021730630X"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.12.018","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}